A targeted and personalised method for triggering the body’s immune response could transform how we treat cancer. Thanks to a grant from the European Research Council (ERC), an inspired idea has been developed in the lab and turned into a ground-breaking commercial opportunity.
Prevention and early detection largely determine the outcome of most cancers. Prof. Päivi Peltomäki studies how tumours arise and progress, with a view to identifying biomarkers of our susceptibility to developing cancer. With the ERC grant, the team has created a single-step, early diagnosis kit for colorectal cancer.